Cholestatic Liver Disease after Rituximab and Adalimumab and the Possible Role of Cross-Reacting Antibodies to Fab 2 Fragments
Joerg Latus(Robert Bosch Hospital), Niko Braun(Stuttgart Observatory), Reinhild Klein(University Children's Hospital Tübingen), Matthias Schwab(Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology), I. Koetter(Robert Bosch Hospital), Mark Dominik Alscher(Robert Bosch Hospital), Péter Fritz, Martin Kimmel(Robert Bosch Hospital)
Cited by 9
Related Papers
A roadmap for graphene
|Nature|2012|9.1k
Reduced Paneth cell α-defensins in ileal Crohn's disease
|Proceedings of the National Academy of Sciences|2005|969
NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal α-defensin expression
|Gut|2004|798
A Chromosome 8 Gene-Cluster Polymorphism with Low Human Beta-Defensin 2 Gene Copy Number Predisposes to Crohn Disease of the Colon
|The American Journal of Human Genetics|2006|566